GRO Biosciences Presents Preclinical Data on Two ProGlytm Programs for Non-Standard Amino Acid Therapies
GRO Biosciences Inc. ("GRObio"), an emerging biotechnology company leveraging synthetic biology to expand the amino acid alphabet and deliver on the promise of protein therapeutics, presented successful proof of concept results in two pre-clinical...
Source: lelezard.com